News releases

Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.

To automatically receive future news releases, please go to the News subscription service page.

[2015] - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002

(click to view the full text)

July 28, 2015
Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology
July 27, 2015
Aeterna Zentaris Commences Promotional Activities for EMD Serono’s Saizen® [Somatropin (rDNA origin) for Injection]
June 30, 2015
Aeterna Zentaris Completes Patient Recruitment for ZoptEC Phase 3 Study with Zoptarelin Doxorubicin in Advanced Endometrial Cancer
June 25, 2015
Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen™ in AGHD
June 18, 2015
Aeterna Zentaris Announces Extension to Regain Compliance with NASDAQ's Minimum Bid Price Rule
May 26, 2015
Aeterna Zentaris’ Confirmatory Phase 3 Study for Macrilen™ in AGHD Meets EMA’s Study-Design Expectations
May 11, 2015
Aeterna Zentaris Announces Election of Directors at 2015 Shareholders’ Meeting
May 8, 2015
Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® [Somatropin (rDNA origin) for Injection] in the U.S.
May 7, 2015
Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results
May 1, 2015
Aeterna Zentaris to Announce First Quarter 2015 Financial and Operating Results on May 7, 2015 and Hold Annual & Special Shareholders Meeting on May 8, 2015
April 27, 2015
Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer
April 23, 2015
Aeterna Zentaris to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference in Toronto
April 16, 2015
Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin
April 13, 2015
Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen™ in AGHD Following Successful Meeting with FDA
March 31, 2015
Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina
March 17, 2015
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results
March 11, 2015
Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants
March 10, 2015
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015
March 6, 2015
Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants
March 5, 2015
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
March 2, 2015
Aeterna Zentaris to Present at Roth Conference 2015
January 6, 2015
Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco